Introduction
============

Most HIV-infected patients in resource-rich settings are successfully treated with combination antiretroviral therapy (ART) \[[@R1]--[@R3]\]. However, up to two-thirds of these patients take a concomitant medication to mitigate ART side effects and/or to treat comorbid conditions \[[@R4]--[@R6]\]. Concomitant medication use is more prevalent in those with HIV than in the general population \[[@R5]\] and has been associated with older age, female sex, obesity and hepatitis B/C coinfection \[[@R4]--[@R7]\]. Concomitant medications could complicate HIV care by contributing to polypharmacy, interactions, side effects and suboptimal adherence.

Polypharmacy (commonly defined as use of five or more medications \[[@R8],[@R9]\]) is associated with increased risk for morbidity, nonadherence, drug interactions and side effects in the general population \[[@R4],[@R6],[@R9],[@R10]\], and is more common in HIV-infected adults than in the general population \[[@R4],[@R11],[@R12]\]. Polypharmacy increases with age \[[@R11],[@R13]\], but is likely underestimated given that most studies in HIV-infected adults only account for prescribed medicines \[[@R4]\]. Polypharmacy of concomitant medications in HIV has been associated with adverse drug reactions leading to hospitalization \[[@R9]\] and suboptimal adherence to ART \[[@R14]\]; however, others have shown that initiation of concomitant medication is favourable to ART adherence \[[@R15]\].

Concomitant medication use in HIV-infected adults increases the risk of pharmacokinetic interactions, particularly in patients receiving a boosted protease or nonnucleoside reverse transcriptase inhibitor (due to cytochrome P450 3A inhibition) \[[@R6],[@R16]\]. Furthermore, pharmacodynamic interactions between ART and concomitant medications can result in additive, antagonistic or synergistic effects of one or the other medication \[[@R17],[@R18]\]. Contraindicated combinations of ART and concomitant medications have been found in 2--7% of ART-treated patients \[[@R6],[@R19]\]. In one cohort, clinically significant drug--drug interactions (DDIs) were found in 27% of patients, and only 35% of these were correctly identified by clinicians \[[@R20]\].

Side effects of ART include nausea, diarrhoea, fatigue, sleep disturbance, myalgia, rash, lipodystrophy and peripheral neuropathy. Concomitant medications may cause similar adverse effects, and it is unknown if adverse effects are more prevalent in those who take concomitant medications or have polypharmacy.

Although there are some data on concomitant medication use and pharmacokinetic ART interactions, recent data on nonprescription medication are sparse, and potential risk factors for polypharmacy have not been evaluated against a broad range of clinical, socio-economic and behavioural parameters. Also, there are no data on adverse effects in HIV-infected patients taking concomitant medication.

Adherence to concomitant medications is important to successful HIV care and patient outcomes related to comorbidity management. Adherence to medication in general is impacted by socio-economic factors, healthcare team/system-related factors, condition-related factors, therapy-related factors and patient-related factors \[[@R21]\]. However, factors related to concomitant medication adherence in HIV patients treated with ART have not been evaluated. Furthermore, the relationship between ART adherence and adherence to concomitant medications is not addressed in the literature.

We previously established a national cohort of Australian adults to evaluate risks for ART failure \[[@R22]\]. The study recorded concomitant medication use. In the present analysis, we evaluated concomitant medication use, polypharmacy, drug interactions, adverse effects and adherence, including risks for polypharmacy and imperfect adherence.

Methods
=======

HIV-infected adults were eligible if they were on ART, had an undetectable HIV plasma viral load, could complete study assessments (interpreter permitted) and had prerequisite standard-of-care blood results available \[HIV RNA, CD4^+^ T-lymphocyte cell count, haemoglobin, estimated glomerular filtration rate (eGFR) and alanine aminotransferase\].

Participants were enrolled at 17 Australian sexual health clinics, hospital clinics and high HIV-caseload general practice sites between September 2013 and November 2015 \[[@R22]\]. Ethical approval was obtained from the Human Research Ethics Committee at each study site, and all participants provided written, informed consent.

We aimed to enrol a representative sample of patients from each site, not excluding patients from any demographic. Sites were instructed to invite all eligible participants sequentially (e.g. every patient at a given clinic or on a clinic day) to avoid selection bias. Enrolling patients at all sites of HIV care (sexual health clinics, hospital clinics and high HIV-caseload general practice sites) allowed for a sample that did not preference only those who may have more complex needs (e.g. those at a hospital site) or, conversely, a younger, more recently diagnosed demographic (e.g. those at a sexual health clinic). Enrolment procedures have been more extensively described previously \[[@R22]\]. The enrolled cohort was diverse and reflective of the HIV epidemic in Australia \[[@R23]\].

Study assessments are described in detail elsewhere \[[@R22]\]. A 204-item questionnaire completed on a dedicated laptop assessed the following themes: socio-demographics, financial and employment status, health care, treatment access, physical health, mental health, quality of life, drug and alcohol use, life stressors, social supports, HIV disclosure, HIV stigma, ART regimen (side effects, use and adherence), ART-related necessity beliefs and concerns and concomitant medication use \[[@R24]--[@R34]\]. Brief neurocognitive screening was completed (Cogstate \[[@R35]\]). Medical and HIV history, serious non-AIDS events (SNAEs) \[[@R36]\], comorbidities, sexually transmitted infections and laboratory data were collected.

Baseline data are presented descriptively as frequencies, percentages and sample means or medians. Multivariate analyses were conducted to determine factors associated with polypharmacy and imperfect concomitant medication adherence \[including sensitivity analyses using backward-stepwise and enter (standard) methods of logistic regression, which yielded similar results (data not shown)\].

Polypharmacy
------------

Polypharmacy of concomitant medications was defined by use of at least five concomitant medications and included use of over-the-counter and alternative medications (but not ART) \[[@R8],[@R9]\]. Polypharmacy was assessed using bivariate analysis with all other covariates, significant covariates (*P* \< 0.05) were included in a forward-step logistic regression model.

Contraindicated medication use, pharmacokinetic or pharmacodynamic interactions
-------------------------------------------------------------------------------

Concomitant medications were examined for DDIs with ART against each product label (Therapeutic Goods Administration Australia and USA Food and Drug Administration current approved) and cross-checked with the University of Liverpool HIV drug interactions database \[[@R37]\]. Combinations were classified as 'no known DDI', 'potential DDI' or 'contraindicated'. Potential DDIs were those listed as having insufficient evidence on coadministration, or evidence of pharmacokinetic or pharmacodynamic interaction, with coadministration accompanied by a caution to prescribers (e.g. increased monitoring, dosage adjustment). Contraindications were identified where there was explicit advice against coprescribing under United States, Australian or European ART guidelines. We did not examine potential DDIs between concomitant medications.

Adverse effects
---------------

Pearson\'s chi-squared test was used to evaluate the relationship between concomitant medication use and between polypharmacy of concomitant medications with each of the following symptoms: nausea, diarrhoea, fatigue, sleep disturbance, muscle pain/weakness, rash, peripheral neuropathy and self-reported lipodystrophy, which could be any fat redistribution.

After analysing adverse effects for associations with polypharmacy, we undertook regression analysis adjusting for comorbid disease burden. Using the previously validated Charlson comorbidity index \[[@R38]\], participants were assigned a score based on the presence or absence of 17 comorbid conditions, with higher scores indicating higher disease burden and mortality risk. All participants were assigned a baseline score of 6 as per the Charlson score for HIV-infection; the index score was entered into the model as a continuous variable, with the binary variable 'polypharmacy: yes or no' also in the model.

Concomitant medication adherence
--------------------------------

Imperfect concomitant medication adherence was defined by patient-reported interruption in the previous 12 months. Covariates were assessed by bivariate analysis with concomitant medication self-reported adherence. Covariates significantly associated with adherence at bivariate analysis (*P* \< 0.05) were included in a forward-step logistic regression model.

All statistical analyses were conducted in IBM SPSS Statistics for Windows, Version 23.0 (IBM Corp., Armonk, New York, USA).

Results
=======

Participants
------------

Baseline characteristics of the 522 participants (significant for concomitant medication use and polypharmacy) are shown in Table [1](#T1){ref-type="table"}. Four hundred and ninety-four (94.6%) were men, mean age was 50.8 years (SD 12.3), median duration of HIV infection was 15.0 years \[interquartile range (IQR) 7.0--25.0\] and median current duration of undetectable viral load was 3.3 years (IQR 1.2--6.8). Supplementary Table 1, lists all covariates (including those that were nonsignificant).

Comorbidities were diagnosed in 292 (55.9%) participants including the following SNAEs: heart disease \[57 (10.9%)\], stroke \[9 (1.7%)\], peripheral vascular disease \[8 (1.5%)\], diabetes \[31 (5.9%)\], chronic liver failure \[2 (0.4%)\] and chronic kidney disease \[14 (2.7%)\]. Seventy (13.4%) participants had hepatitis coinfection, and 97 (18.6%) reported symptoms consistent with 'major depressive disorder' \[patient health questionnaire (PHQ-9) \[[@R24]\]\].

ART regimens are listed in Supplementary Table 2. Once-daily ART was prescribed to 333 (63.7%) participants, and 158 (30.3%) participants took a single-tablet regimen (STR), 138 (26.4%) took a boosted protease inhibitor. Alcohol, cigarette and recreational drug use are shown in Supplementary Table 3.

Concomitant medication use
--------------------------

Of the 522 participants, 392 (75.1%) took at least one concomitant medication, and 363 (92.6%) of those had at least one prescribed medication (versus over-the-counter, herbal/alternative medications). Among participants who took a concomitant medication, the daily concomitant pill burden was 6.0 (SD 4.5), whereas the sample ART daily pill burden was 1.2 (SD 0.4). The most common classes of concomitant medications taken were cardiovascular agents, nonprescription (vitamins, minerals and alternative therapies), antidepressants, endocrine agents and antiinfectives (Fig. [1](#F1){ref-type="fig"}).

![Concomitant medications by system/type.](aids-32-35-g001){#F1}

Polypharmacy
------------

Of those on a concomitant medication, 122 (31%) took at least five concomitant medications (23% of all participants). Covariates significantly associated with polypharmacy in bivariate analysis are listed in Table [2](#T2){ref-type="table"}. Those independently associated with polypharmacy were enrolment in a randomized trial \[adjusted odds ratio (AOR) 3.5\], an eGFR less than 60 ml/min per 1.73 m^2^ (AOR 3.8), a known comorbidity or SNAE (AOR 4.2), HIV management in a hospital-based clinic (AOR 2.0) or in a general practice (AOR 1.9) versus a sexual health clinic; and monthly or greater use of benzodiazepines (AOR 2.8).

Pharmacokinetic and pharmacodynamic interactions
------------------------------------------------

Of the 392 participants on a concomitant medication, 17 (4.3%) participants (3.3% of all participants) were taking a concomitant medication contraindicated with their ART. Contraindicated combinations detected were ritonavir (budesonide, fluticasone, meloxicam, quetiapine, rivaroxaban, simvastatin), darunavir (salmeterol), rilpivirine (esomeprazole, omeprazole, pantoprazole), atazanavir (esomeprazole, fluticasone, pantoprazole, quetiapine, rabeprazole, rivaroxaban, simvastatin), lopinavir (fluticasone) and saquinavir (budesonide, citalopram, sildenafil, tadalafil).

Five of the 17 participants took two contraindicated combinations, and one took four contraindicated combinations.

In total, 730 ART-concomitant medication combinations in 237 (60.5%) of the 392 participants were identified as having a potential for DDI. These were most commonly related to protease inhibitor use. For example, 223 combinations existed between ritonavir and concomitant medications \[e.g. ritonavir with rosuvastatin (29 occurrences), atorvastatin (15 occurrences), mirtazapine (13 occurrences), oxycodone (two occurrences) or sildenafil (eight occurrences)\]; and 115 combinations with darunavir \[e.g. darunavir with diazepam (eight occurrences), budesonide/formoterol (two occurrences) or rosuvastatin (15 occurrences)\]. From drug classes other than protease inhibitors, efavirenz contributed 83 potential DDIs. For over-the-counter concomitant medications, the most common interactions identified were between integrase inhibitors and supplements containing magnesium or calcium \[27 (4% of total DDI combinations)\].

Polypharmacy, pharmacokinetic and pharmacodynamic interactions taken together
-----------------------------------------------------------------------------

Two hundred and eighty (53.6%) participants had at least one of polypharmacy, pharmacokinetic/pharmacodynamic interaction or contraindication (Supplementary Table 4).

Adverse effects and concomitant medication use or polypharmacy
--------------------------------------------------------------

Adverse symptoms were reported by 178 (34.1%) participants, most commonly sleep disturbance \[156 (29.9%)\], diarrhoea \[135 (25.8%)\] and nausea \[110 (21.1%)\]. Concomitant medication use was significantly associated with sleep disturbance \[odds ratio (OR) 2.6, 95% confidence interval (CI) 1.5--4.2, *P* \< 0.001\], lipodystrophy (OR 6.0, 95% CI 2.2--17.0, *P* \< 0.001) and myalgia (OR 2.1, 95% CI 1.1--3.9, *P* = 0.019). Polypharmacy of concomitant medication was significantly associated with diarrhoea (OR 1.6, 95% CI 1.0--2.4, *P* = 0.046), lipodystrophy (OR 2.4, 95% CI 1.4--4.1, *P* = 0.001), fatigue (OR 1.7, 95% CI 1.1--2.6, *P* = 0.015), myalgia (OR 1.7, 95% CI 1.0--2.9, *P* = 0.033) and peripheral neuropathy (OR 3.9, 95% CI 2.4--6.4, *P* \< 0.001).

In bivariate analyses, a higher Charlson index score was associated with the adverse effects of lipodystrophy (*P* = 0.001) and peripheral neuropathy (*P* \< 0.001), but not with any of the other adverse effects reported. When adjusted for disease burden (using the Charlson index score), polypharmacy remained significantly associated with diarrhoea (AOR 1.9, 95% CI 1.1--3.0, *P* = 0.013), fatigue (AOR 1.7, 95% CI 1.0--2.6, *P* = 0.032) and peripheral neuropathy (AOR 3.1, 95% CI 1.8--5.2, *P* ≤ 0.001). Higher comorbid disease burden was significantly associated with lipodystrophy (AOR 1.2, 95% CI 1.1--1.5, *P* = 0.012), and neither polypharmacy nor disease burden were statistically significantly associated with myalgia in the adjusted model.

Concomitant medication adherence
--------------------------------

Of the 392 participants on concomitant medications, 60 (15.3%) reported missed doses in the previous 12 months, of which 37 (61.7%) interrupted their concomitant medications for at least 1 week. This was a higher proportion than those who self-reported missing ART for greater than or equal to a week in the same period \[20 participants (3.8%)\] (Supplementary Table 5).

Results of the bivariate analyses of concomitant medication adherence are shown in Table [3](#T3){ref-type="table"}. Four covariates were independently associated with imperfect concomitant medication adherence requiring financial support (AOR 27.8), foregoing necessities for financial reasons (AOR 11.1), good or very good self-reported health (AOR 14.1) and at least 1 bed day for illness in the previous 12 months (AOR 14.0).

Discussion
==========

In this sample of HIV-infected Australian adults, 75% took a concomitant medication, and 54% of participants had one or more of polypharmacy (23%), pharmacokinetic or pharmacodynamic interaction (45%) or contraindication (3%). Over 700 potential DDIs were identified. Sixty (11.5%) reported imperfect concomitant medication adherence. Multiple adverse symptoms were more common in those taking concomitant medication.

Over 90% of patients taking a concomitant medication took at least one prescribed concomitant medication, but many were also on complementary/alternative medication and over-the-counter preparations. Patient disclosure of over-the-counter or complementary therapy usage is often underestimated \[[@R39]\]. One meta-analysis of 40 studies investigating complementary medicine use in HIV-infected adults found an average of 60% of patients use complementary medications -- more likely in MSM, nonminority, better educated and less impoverished patients \[[@R39]\].

In our sample, financial barriers were associated with imperfect adherence to concomitant medications, whether this more specifically related to complementary medicines is unknown.

Participants also self-reported taking prescription medications recreationally, as well as other classes of recreational drugs at similar rates to other Australian surveys \[[@R40]\].

The mean age of our cohort was 51 years, and over half (56%) had at least one known comorbidity. This is consistent with other cohorts that have found at least one comorbidity in 58 \[[@R41]\] to 70% \[[@R42]\] of HIV-infected patients over 50 years of age. Noncommunicable diseases, and multiple conditions at once, are more common in HIV-infected adults than in the general population \[[@R41],[@R43]\], and increase with age \[[@R42]\]. In fact in one study, the prevalence of at least two noncommunicable diseases in HIV-infected adults across all age groups was similar to the prevalence of those 10 years older in the general population \[[@R41]\]. In our cohort, polypharmacy was independently associated with a low eGFR and a diagnosed comorbidity/SNAE; these findings support the literature reporting that the likelihood of polypharmacy increases with age \[[@R4]\], and the high proportion of concomitant medications and polypharmacy in our cohort is not surprising given the high rates of comorbid conditions.

HIV care at a hospital-based clinic or a general practice site also independently associated with polypharmacy; those managed at a sexual health clinic/service may have fewer chronic medical needs (or alternatively the need for concomitant medications was less well scrutinized). Clinical trial participation was also significantly associated with polypharmacy. Patients who are selected for clinical trial participation may be more engaged in care, compliant, motivated or health-seeking, thereby also more likely to initiate and remain on a concomitant medication.

The only recreational drug class to maintain significant association with polypharmacy was benzodiazepines. Participants self-reported nonprescribed benzodiazepine use with other commonly used recreational drugs, and participants may have over-reported (providing detail regarding prescribed use).

Given that ART usually consists of three antiretroviral agents (either individually or coformulated), our definition of polypharmacy was conservative, as participants defined as having polypharmacy were in fact mostly taking at least eight medicines \[[@R4]\]. Had we included antiretroviral medications in our definition of polypharmacy, the proportion taking at least five medications would be 59% (not 23%).

As pill burden (in addition to polypharmacy) is associated with nonadherence to medications in the literature, the positive gains of STRs for ART may be offset by the higher concomitant medication pill-burden, potentially reducing both ART and concomitant medication adherence. The benefit of single-tablet ART regimens might, therefore, be more effective if concomitant medications were likewise coformulated and minimized as much as possible. However, an Italian study found patients with polypharmacy were less likely to be on a single-tablet ART regimen, hypothesizing this may be a prescribing choice made due to the restricted capacity to manage drug interactions and the decision to avoid pharmacodynamic interactions caused by tenofovir disoproxil fumarate or abacavir (commonly found in coformulated ART at the time of analysis) \[[@R44]\]. New STRs with less likelihood for interactions are required.

Contraindicated ART-concomitant medication combinations were uncommon (3%), a similar prevalence to that found in the Swiss cohort study (2%) \[[@R6]\] and a large US cohort (7%) \[[@R19]\]. Potential DDIs were far more common, but their clinical relevance is unknown. Further work evaluating dosing modifications and clinical monitoring adjustments made to prevent or monitor DDIs, and longitudinal studies of patient outcomes would be useful to determine the clinical importance of the DDIs.

Our analysis is novel in its finding that polypharmacy of concomitant medication was significantly associated with diarrhoea, lipodystrophy, fatigue, muscle pain/weakness and peripheral neuropathy. These symptoms may represent adverse effects of ART or of concomitant medications, or may indicate use of concomitant medications to alleviate adverse effects. We adjusted for the presence and severity of comorbidities using the Charlson index, a validated measure of disease burden \[[@R45]\]; this index provided an objective tool to evaluate the impact of comorbidities in analysing the association between polypharmacy and adverse effects. Three of the five adverse effects remained statistically significantly associated with polypharmacy after adjustment for Charlson score: diarrhoea, fatigue and peripheral neuropathy. Although our data are unable to clarify causality, this finding is notable in that polypharmacy is associated with adverse effects even when adjusted for comorbid disease burden.

Of the above symptoms, it is perhaps more likely that lipodystrophy and neuropathy are ART related, given that they are known side effects of ART; although fatigue and myalgia may be more likely to be concomitant medication related, as these symptoms are not likely to lead directly to prescription of concomitant medication. The adverse effects examined are unlikely due to HIV *per se*, as all patients had undetectable viral loads and the vast majority (90%) had a CD4^+^ T-lymphocyte cell count more than 350 cells/μl.

Imperfect adherence to concomitant medication was independently associated with financial burden (requiring financial support, or going without necessities for financial reasons) and overall wellness (self-reported good/very good general health, or having ≥1 bed day for illness in the previous 12 months). These seemingly paradoxical results suggest that participants are less likely to take their concomitant medications when they are feeling much worse or very well. Conversely, some participants might be reporting poorer health as they don't take all of their concomitant medication, or ART.

We hypothesized that participants who took concomitant medications or had polypharmacy of concomitant medications would be less adherent to their ART. In our cohort, participants were more likely to be nonadherent to concomitant medications than ART. However, in regression analysis, the association between suboptimal concomitant medication adherence and suboptimal ART adherence did not maintain significance. Furthermore, polypharmacy was not associated with suboptimal ART adherence. Others have found HIV patients to prioritize ART over concomitant medications; one small single-centre study demonstrated a higher level of necessity scores and lower concern scores for ART than concomitant medications, increasing for those patients on at least two concomitant medications \[[@R46]\]. Our questionnaire only assessed necessity and concern scores for ART and we are, therefore, unable to compare these with beliefs regarding concomitant medications in our cohort. However, the higher level of adherence to ART than concomitant medications may indicate participants prioritise ART over concomitant medications.

A previous analysis examined suboptimal ART adherence in this cohort \[[@R22]\]. The covariates independently associated with suboptimal ART adherence and with concomitant medication adherence were the socio-economic variables of financial strain in this analysis, whereas in the prior analysis, it was living in subsidized housing. It may be participants who are under financial strain prioritize ART maintenance over concomitant medications. However, financial strain was significantly associated with both ART and non-ART adherence.

Our study has limitations. We reported on a mainly male population of HIV-infected adults enrolled in a country where medications are highly subsidized. However, the enrolled cohort is demographically representative of HIV-infected patients in Australia and other cohorts such as the Australian HIV Observational Database \[[@R23]\]. These results cannot necessarily be generalized to women or children, or to countries with different socio-economic contexts or without universally subsidized healthcare systems. In our sample, it is unknown which concomitant medications were interrupted. Our data are cross-sectional, so we were unable to evaluate whether any harm was incurred due to pharmacokinetic/pharmacodynamic interactions. This study did not ask for data on concomitant medication dosage, so we are unable to report on dose adjustments that might mitigate potential DDIs. In our effort to design a comprehensive study looking at a wide range of medical, socio-demographic and social variables we assessed a large number of variables that create a risk of collinearity. However, sensitivity analyses were performed to ensure key variables were consistently significant across all models.

As HIV-infected patients continue to live longer, it is important to manage concomitant medications, so that they do not cause harm or reduce ART adherence or potency. Over half of our sample had one or more of polypharmacy or drug interaction; efforts should be made to minimize polypharmacy, to develop new antiretrovirals with fewer drug interactions and to prescribe concomitant medications that do not cause side effects.
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###### Supplemental Digital Content

###### 

Sample characteristics by concomitant medication exposure (significant covariates).

                                                                                                                                                        Concomitant medications                                             
  --------------------------------------------------------------------------------------------------------------------------------------- ------------- ------------------------- ------------- ------------- ------------- ---------
  Demographic characteristics                                                                                                                                                                                               
   Age (years; mean, SD)                                                                                                                  50.8 (12.3)   41.9 (12.4)               53.8 (10.8)   52 (11.0)     57.4 (9.4)    \<0.001
   Sex (male)                                                                                                                             494 (94.6)    117 (90.0)                376 (96.0)    256 (94.8)    120 (98.4)    0.006
   Australian born                                                                                                                        322 (61.6)    62 (47.7)                 259 (66.1)    172 (63.7)    87 (71.3)     \<0.001
   Living alone                                                                                                                           212 (40.5)    28 (21.5)                 183 (46.7)    117 (43.3)    66 (54.1)     \<0.001
   Speaks English at home                                                                                                                 493 (94.3)    110 (84.6)                382 (97.4)    261 (96.7)    121 (99.2)    \<0.001
   Australian citizen                                                                                                                     461 (88.1)    98 (75.4)                 362 (92.3)    245 (90.7)    117 (95.9)    \<0.001
   Has Medicare access                                                                                                                    508 (97.1)    120 (92.3)                387 (98.7)    266 (98.5)    121 (99.2)    0.001
   Met Medicare safety net[^a^](#TF1-1){ref-type="table-fn"} in last 12 months                                                            94 (18.0)     12 (9.2)                  81 (20.7)     40 (14.8)     41 (33.6)     \<0.001
   Has private health insurance                                                                                                           221 (42.3)    63 (48.5)                 158 (40.3)    119 (44.1)    39 (32.0)     0.010
  Financial/employment status                                                                                                                                                                                               
   On social welfare                                                                                                                      212 (40.6)    21 (16.2)                 191 (48.7)    110 (40.7)    81 (66.4)     \<0.001
   Required financial assistance in last 12 months                                                                                        138 (26.4)    23 (17.7)                 127 (32.4)    78 (28.9)     49 (40.2)     \<0.001
   Unemployed                                                                                                                             226 (43.2)    33 (25.4)                 193 (49.2)    111 (41.1)    82 (67.2)     \<0.001
   Lives in public-subsidized accommodation                                                                                               105 (20.1)    12 (9.2)                  92 (23.5)     51 (18.9)     41 (33.6)     \<0.001
   In previous 12 months, for financial reasons, had to forego food, groceries, rent, household bills, furniture, clothing, white goods   114 (21.8)    17 (13.1)                 97 (24.7)     62 (23.0)     35 (28.7)     0.004
  HIV healthcare and treatment access                                                                                                                                                                                       
   Uses the following for HIV management                                                                                                                                                                                    
    Hospital-based HIV clinic                                                                                                             254 (48.7)    59 (45.4)                 195 (49.7)    123 (45.6)    72 (59.0)     0.039
    Community-based general practice                                                                                                      174 (33.3)    16 (12.3)                 158 (40.3)    95 (35.2)     63 (51.6)     \<0.001
    Sexual health clinic/centre                                                                                                           168 (32.2)    56 (43.1)                 112 (28.6)    79 (29.3)     33 (27.0)     0.007
    Hospital pharmacy                                                                                                                     259 (49.6)    44 (33.8)                 215 (54.8)    137 (50.7)    78 (63.9)     \<0.001
    Drug or alcohol services                                                                                                              9 (1.7)       --                        9 (2.3)       5 (1.9)       4 (3.3)       0.044
    HIV community organization or support group                                                                                           77 (14.8)     15 (11.5)                 62 (15.8)     32 (11.9)     30 (24.6)     0.004
   Primary HIV physician                                                                                                                                                                                                    
    General practitioner                                                                                                                  181 (34.7)    27 (20.8)                 154 (39.3)    106 (39.3)    48 (39.3)     0.001
    Sexual health physician                                                                                                               114 (21.8)    41 (31.5)                 73 (18.6)     55 (20.4)     18 (14.8)     0.001
   Study enrolment site                                                                                                                                                                                                     
    High-caseload general practice                                                                                                        145 (27.8)    8 (6.2)                   137 (34.9)    92 (34.1)     45 (36.9)     \<0.001
    Hospital-located clinic                                                                                                               174 (33.3)    31 (23.8)                 143 (36.5)    92 (34.1)     51 (41.8)     0.002
    Sexual health clinic/centre                                                                                                           203 (38.9)    91 (70.0)                 112 (28.6)    86 (31.9)     26 (21.3)     \<0.001
   Duration of care from primary HIV physician (years; mean, SD)                                                                          11.3 (8.0)    7.6 (6.9)                 12.4 (8.0)    11.5 (8.0)    14.6 (7.8)    \<0.001
   Changed primary HIV physician in last 12 months                                                                                        80 (15.3)     32 (24.6)                 51 (13.0)     37 (13.7)     14 (11.5)     0.016
   Seen other medical specialist in last 12 months                                                                                        321 (61.5)    60 (46.2)                 261 (66.6)    167 (61.9)    95 (77.9)     \<0.001
   Other healthcare providers involved in HIV care                                                                                        324 (62.1)    63 (48.5)                 261 (66.6)    169 (62.6)    92 (75.4)     \<0.001
   Cost of non-HIV medications (A\$, last 3 months; mean, SD)                                                                             145 (434)     107 (644)                 157 (335)     129 (187)     224 (537)     0.041
  HIV history                                                                                                                                                                                                               
   HIV diagnosed prior to 1996                                                                                                            213 (40.8)    22 (16.9)                 191 (48.7)    113 (41.9)    78 (63.9)     \<0.001
   Nadir CD4^+^ T-lymphocyte cell count \<200 cells/μl                                                                                    202 (38.7)    34 (26.2)                 168 (42.9)    112 (41.5)    56 (45.9)     \<0.001
   Previous AIDS                                                                                                                          120 (22.9)    13 (10.0)                 107 (27.3)    62 (23.0)     45 (36.9)     \<0.001
  Comorbidities                                                                                                                                                                                                             
   Heart disease                                                                                                                          57 (10.9)     2 (1.5)                   55 (14.0)     24 (8.9)      31 (25.4)     \<0.001
   Hypertension                                                                                                                           94 (18.0)     2 (1.5)                   92 (23.5)     51 (18.9)     41 (33.6)     \<0.001
   Stroke                                                                                                                                 9 (1.7)       --                        9 (2.3)       3 (1.1)       6 (4.9)       0.003
   Peripheral vascular disease                                                                                                            8 (1.50)      --                        8 (2.0)       3 (1.1)       5 (4.1)       0.008
   Diabetes                                                                                                                               31 (5.9)      --                        31 (7.9)      13 (4.8)      18 (14.8)     \<0.001
   Chronic liver failure                                                                                                                  2 (0.4)       --                        2 (0.5)       --            2 (1.6)       0.038
   Chronic kidney disease                                                                                                                 14 (2.7)      --                        14 (3.6)      8 (3.0)       6 (4.9)       0.015
   Other diagnosed comorbidity[^b^](#TF1-2){ref-type="table-fn"}                                                                          102 (19.5)    7 (5.4)                   95 (24.2)     62 (23.0)     33 (27.0)     \<0.001
  Current health                                                                                                                                                                                                            
   Length of undetectable HIV viral load \>1 year                                                                                         399 (76.4)    91 (70.0)                 308 (78.6)    205 (76.0)    103 (84.4)    0.007
   Currently enrolled on a clinical trial                                                                                                 45 (8.6)      4 (3.1)                   41 (10.5)     25 (9.3)      16 (13.1)     0.004
   eGFR \<60 ml/min per 1.73 m^2^                                                                                                         43 (8.2)      6 (4.6)                   37 (9.4)      14 (5.2)      23 (18.9)     \<0.001
   Hepatitis B or C coinfection                                                                                                           70 (13.4)     3 (2.3)                   65 (16.6)     46 (17.0)     19 (15.6)     0.001
   Sexually transmitted infection in last 12 months                                                                                       71 (13.6)     28 (21.5)                 42 (10.7)     33 (12.2)     9 (7.4)       0.001
   Hospitalized for ≥1 night in last 12 months                                                                                            108 (20.7)    16 (12.3)                 92 (23.5)     57 (21.1)     35 (28.7)     0.001
  Physical health                                                                                                                                                                                                           
   Self-reported good/very good overall health                                                                                            435 (83.3)    118 (90.8)                316 (80.6)    223 (82.6)    93 (76.2)     0.002
   ≥1 Doctor visits for illness in last 12 months                                                                                         358 (68.6)    83 (63.8)                 275 (70.2)    184 (68.1)    91 (74.6)     0.044
  Mental health                                                                                                                                                                                                             
   Major depressive disorder (PHQ-9 \[[@R24]\])                                                                                           87 (16.7)     12 (9.2)                  75 (19.1)     45 (16.7)     30 (24.6)     0.001
   Psychiatric illness -- currently clinically active                                                                                     112 (24.3)    4 (3.1)                   108 (27.6)    66 (24.4)     42 (34.4)     \<0.001
  Alcohol and drug use                                                                                                                                                                                                      
   Benzodiazepines                                                                                                                        39 (7.5)      --                        39 (9.9)      18 (6.7)      21 (17.2)     \<0.001
   PDE5 inhibitor ('viagra' or 'similar')                                                                                                 67 (12.8)     9 (6.9)                   58 (14.8)     36 (13.3)     22 (18.0)     0.008
   Opiates                                                                                                                                11 (2.1)      --                        11 (2.8)      4 (1.5)       7 (5.7)       0.002
  Life stressors                                                                                                                                                                                                            
   \>2 Major stress events in last 12 months                                                                                              133 (25.5)    20 (15.4)                 113 (28.8)    76 (28.1)     37 (30.3)     0.005
  Social support                                                                                                                                                                                                            
   Married/*de facto*/in regular relationship                                                                                             226 (43.2)    64 (49.2)                 158 (40.3)    147 (54.4)    87 (71.3)     0.001
   In serodiscordant sexual relationship                                                                                                  136 (26.0)    46 (35.4)                 90 (23.0)     71 (26.3)     19 (15.6)     0.047
   Not linked to an HIV support organization                                                                                              388 (74.3)    115 (88.5)                330 (84.2)    238 (88.1)    92 (75.4)     0.004
  Antiretroviral therapy                                                                                                                                                                                                    
   ART as a single-tablet regimen                                                                                                         158 (30.3)    55 (42.3)                 103 (26.3)    81 (30.0)     22 (18.0)     \<0.001
   Once-daily ART dosing                                                                                                                  333 (63.7)    102 (78.5)                231 (58.9)    169 (62.6)    62 (50.8)     \<0.001
   Commenced ART within 1 year of diagnosis                                                                                               245 (46.8)    77 (59.2)                 168 (42.9)    118 (43.7)    50 (41.0)     \<0.001
   Commenced ART prior to 2004                                                                                                            247 (47.3)    26 (20.0)                 221 (56.4)    134 (50.0)    87 (71.3)     \<0.001
   When started ART felt 'not at all'/'only somewhat' informed about ART                                                                                                                                                    
    Side effects                                                                                                                          178 (34.1)    34 (26.2)                 144 (36.7)    95 (35.2)     49 (40.2)     0.020
    Benefits                                                                                                                              115 (22.0)    18 (13.8)                 97 (24.7)     57 (21.1)     40 (32.8)     \<0.001
    Dosing requirements                                                                                                                   44 (8.4)      7 (5.4)                   37 (9.4)      22 (8.1)      15 (12.3)     0.045
    Lifestyle impacts                                                                                                                     151 (28.9)    26 (20.0)                 125 (31.9)    79 (29.3)     46 (37.7)     0.002
    Own ART regimen                                                                                                                       106 (20.3)    16 (12.3)                 90 (23.0)     56 (20.7)     34 (27.9)     0.003
   Reason for starting ART: to prevent transmission to HIV-negative partners                                                              101 (19.5)    36 (27.7)                 65 (16.6)     45 (16.7)     20 (16.4)     0.023
   Never speaks with HIV doctors or nurses about: cost burden of ART                                                                      425 (82.1)    95 (73.1)                 330 (84.2)    227 (84.1)    103 (84.4)    0.025
   Sometimes stops taking ART medications if feeling worse                                                                                48 (9.2)      4 (3.1)                   44 (11.2)     27 (10.0)     17 (13.9)     0.005
   Experienced ART side effects in last 12 months                                                                                         297 (56.9)    62 (47.7)                 235 (59.9)    156 (57.8)    79 (64.8)     0.007
   Delayed/interrupted ART prior to 12 months ago                                                                                         85 (17.5)     9 (6.9)                   76 (19.4)     52 (19.3)     24 (19.7)     0.024
  Concomitant medications                                                                                                                                                                                                   
   Medications per day (mean, SD)                                                                                                         3.6 (4.3)     0 (0.0)                   4.7 (4.4)     2.7 (2.0)     9.3 (4.9)     \<0.001
   Delayed/interrupted last 12 months                                                                                                     60 (14.0)     4 (3.1)                   56 (14.3)     32 (11.9)     24 (19.7)     0.001
   Delayed/interrupted prior to 12 months ago                                                                                             49 (12.3)     3 (2.3)                   46 (11.7)     26 (9.6)      20 (16.4)     0.007
  PROQOL HIV                                                                                                                                                                                                                
   PROQOL HIV summary score[^c^](#TF1-3){ref-type="table-fn"} (mean, SD)                                                                  40.1 (23.4)   41.8 (21.4)               41.7 (24.1)   40.8 (24.1)   49.8 (25.0)   0.005

ART, antiretroviral therapy; eGFR, estimated glomerular filtration rate; PDE5, phosphodiesterase type 5 inhibitor; PROQOL HIV, the patient reported outcomes quality of life - HIV.

^a^Whereby medical costs -- including pharmaceutical copayments, are capped after reaching an annual threshold.

^b^Other diagnosed comorbidities include: depression \[6 (1.1%)\], erectile dysfunction \[6 (1.1%)\], osteoarthritis \[5 (1.0%)\] Chronic Obstructive Pulmonary Disease \[4 (0.8%)\] and asthma \[4 (0.8%)\].

^c^Sample summary score (mean) (higher score indicative of lower quality of life).

^\*^*P* value for trend: no comedication(s), 1--4 comedication(s), polypharmacy (≥5 comedications).

###### 

Polypharmacy of concomitant medications.

                                                                                                                       Polypharmacy                                                       
  -------------------------------------------------------------------------------------------------------------------- -------------- ----- ----- ----------- --------- ----- ----------- ---------
  Socio-demographic                                                                                                                                                                       
   Male                                                                                                                120            373   4.3   1.0--18.5   0.031                       
   \>51 Years old                                                                                                      89             183   3.2   2.0--5.0    \<0.001                     
   Australian born                                                                                                     87             234   1.8   1.1--2.7    0.011                       
   Australian citizen                                                                                                  117            343   3.9   1.5--9.9    0.002                       
   Lives alone                                                                                                         66             145   2.1   1.4--3.1    \<0.001                     
   Not in a relationship                                                                                               87             211   2.2   1.4--3.5    \<0.001                     
   Not currently in a sexual relationship                                                                              84             218   1.8   1.2--2.8    0.005                       
   English spoken at home                                                                                              121            371   9.5   1.3--70.2   0.008                       
   Self-rated ability to read, speak and understand English as 'below average/poor'                                    6              7     2.9   1.0--8.8    0.049                       
   Uses NGO/community outreach for assistance in HIV care in last 12 months                                            30             47    2.5   1.5--4.0    \<0.001                     
  Finances and employment                                                                                                                                                                 
   No private health insurance                                                                                         83             218   1.8   1.2--2.7    0.008                       
   Lives in subsidized housing                                                                                         41             63    2.7   1.7--4.3    \<0.001                     
   Income from social welfare                                                                                          81             131   4.1   2.6--6.2    \<0.001                     
   Not working                                                                                                         82             144   3.6   2.3--5.5    \<0.001                     
   Required financial assistance/support for necessities (e.g. food, rent, household bills), over previous 12 months   49             88    2.4   1.5--3.7    \<0.001                     
   Went without necessities for financial reasons, over previous 12 months                                             35             79    1.6   1.0--2.6    0.036                       
   Required financial assistance for government subsidized/nonsubsidized pharmaceuticals/disorder testing              57             89    3.1   2.0--4.7    \<0.001                     
   Not paying to see general practitioner (e.g. GP bulk bills)                                                         62             90    3.4   1.7--7.1    0.001                       
   Not spending money on any HIV services (e.g. no out-of-pocket HIV services cost)                                    75             212   1.7   1.1--2.6    0.029                       
   Spending less than the sample median for ART costs                                                                  73             192   1.7   1.1--2.6    0.015                       
   Spending more than the sample median on concomitant medication costs                                                73             175   2.3   1.5--3.5    \<0.001                     
   Reached the Medicare Safety Net in the previous 12 months[^b^](#TF2-2){ref-type="table-fn"}                         50             80    2.8   1.8--4.3    \<0.001                     
  Physical health                                                                                                                                                                         
   Diagnosed comorbidity                                                                                               103            189   6.3   3.7--10.7   \<0.001   4.2   2.0--8.6    \<0.001
   Not being diagnosed with an STI in the previous 12 months                                                           112            339   2.2   1.1--4.7    0.027                       
   Previous AIDS                                                                                                       45             75    2.5   1.6--4.0    \<0.001                     
   Self-rated health as poor                                                                                           29             59    1.8   1.1--3.0    0.020                       
   ≥1 Overnight hospitalization in the previous 12 months                                                              35             73    1.8   1.1--2.9    0.013                       
   Estimated glomerular filtration rate \<60 ml/min per 1.73 m^2^                                                      23             20    4.4   2.3--8.4    \<0.001   3.8   1.5--10.1   0.006
   Delayed or interrupted concomitant medications in the previous 12 months                                            24             36    2.0   1.2--3.6    0.013                       
   Delayed or interrupted concomitant medications prior to 12 months ago                                               20             29    1.9   1.0--3.5    0.044                       
  Mental health                                                                                                                                                                           
   Major depressive disorder                                                                                           30             57    2.0   1.2--3.2    0.007                       
  Drug use (at least monthly)                                                                                                                                                             
   Benzodiazepines ('benzos')                                                                                          21             18    4.4   2.3--8.6    \<0.001   2.8   1.1--7.7    0.035
   Steroids                                                                                                            8              4     6.9   2.1--23.5   \<0.001                     
   Opiates                                                                                                             7              4     6.1   1.7--21.0   0.001                       
  HIV healthcare and treatment access                                                                                                                                                     
   HIV managed by a hospital based clinic[^c^](#TF2-3){ref-type="table-fn"}                                            72             182   1.7   1.1--2.6    0.009     2.0   1.0--3.6    0.030
   HIV managed in a general practice[^c^](#TF2-3){ref-type="table-fn"}                                                 63             111   2.8   1.8--4.2    \<0.001   1.9   1.0--3.7    0.038
   Accessed hospital-based pharmacy                                                                                    78             181   2.1   1.4--2.5    \<0.001                     
   Receiving care from primary HIV physician for longer than the sample mean (\>10 years)                              88             178   3.2   2.0--5.0    \<0.001                     
   Other specialist(s) involved in care                                                                                95             226   2.7   1.7--4.3    \<0.001                     
   Other healthcare providers involved in HIV care/treatment                                                           92             232   2.2   1.4--3.5    0.001                       
   Enrolled in a randomized clinical trial                                                                             16             29    1.9   1.0--3.7    0.040     3.5   1.3--9.0    0.011
   Diagnosed with HIV pre-2010                                                                                         114            318   4.1   1.9--92     \<0.001                     
  ART regimen, side effects, consistent use, adherence                                                                                                                                    
   Commenced ART prior to 2004                                                                                         87             160   4.2   2.6--6.6    \<0.001                     
   Protease-inhibitor containing regimen                                                                               57             134   1.8   1.2--2.7    0.006                       
   ART side effects                                                                                                    79             218   1.5   1.0--2.3    0.045                       
   \>1 ART tablet per day                                                                                              99             262   2.3   1.4--3.9    0.001                       
   More than once-daily ART dosing                                                                                     59             127   2.0   1.3--3.1    0.001                       
   More than 1 year undetectable HIV viral load                                                                        103            296   2.0   1.1--3.4    0.016                       
   Stops taking ART when feeling worse                                                                                 17             31    1.9   1.0--3.6    0.039                       

AOR, adjusted odds ratio; ART, antiretroviral therapy; CI, confidence interval; GP, general practitioner; NGO, non-governmental organization; OR, odds ratio; STI, sexually transmitted infection.

^a^Spending more than the sample mean on concomitant medications was intentionally removed from modelling, due to the linear relationship between more medications and increased spending.

^b^Whereby there is no out-of-pocket/'gap' payment for GP services above the Medicare standard rebate.

^c^Versus a sexual health clinic/centre.

###### 

Adherence to concomitant medications.

                                                                                                                                                                        Concomitant medication interruption                                                          
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------- ----- ------ ------------- --------- ------ ---------- -------
  Sociodemographic                                                                                                                                                                                                                                                   
   Not in a relationship                                                                                                                                                44                                    206   2.2    1.2--4.0      0.011                       
   Currently in a sexual relationship                                                                                                                                   43                                    213   1.9    1.0--3.4      0.041                       
   Self-rated ability to read, speak and understand English as 'below average/poor'                                                                                     4                                     5     5.2    1.4--20.0     0.008                       
   Receives less social support than would like/required                                                                                                                44                                    218   1.9    1.0--3.5      0.036                       
   Participates in a NGO/community outreach for assistance in HIV management -- as an active participant in previous 12 months                                          29                                    88    3.0    1.7--5.2      \<0.001                     
  Finances and employment                                                                                                                                                                                                                                            
   No private health insurance                                                                                                                                          47                                    204   2.9    1.5--5.6      0.001                       
   Lives in subsidized housing                                                                                                                                          21                                    73    2.2    1.2--3.9      0.008                       
   On social welfare                                                                                                                                                    40                                    149   3.0    1.7--5.3      \<0.001                     
   Unemployed                                                                                                                                                           38                                    157   2.4    1.4--4.3      0.002                       
   Required financial assistance/support for necessities (e.g. food, rent, household bills), over the previous 12 months                                                35                                    87    4.5    2.6--8.0      \<0.001   27.8   1.8--440   0.018
   Went without necessities for financial reasons, over the previous 12 months                                                                                          26                                    75    3.0    1.7--5.3      \<0.001   11.1   1.9--114   0.042
   Paid less than sample mean for ART (last time obtained)                                                                                                              40                                    186   1.9    1.1--3.5      0.026                       
  Physical health                                                                                                                                                                                                                                                    
   At least one comorbidity or SNAE                                                                                                                                     49                                    213   3.2    1.6--6.3      0.001                       
   Concomitant medication daily pill burden greater than the sample mean                                                                                                39                                    178   2.0    1.1--3.5      0.017                       
   Delayed or interrupted concomitant medications prior to 12 months ago                                                                                                38                                    11    66.0   28.8--151.4   \<0.001                     
   Good/very good self-reported general health                                                                                                                          29                                    50    6.0    3.3--10.7     \<0.001   14.1   1.4--141   0.025
   ≥1 Bed day for illness in previous 12 months                                                                                                                         44                                    198   2.5    1.3--4.6      0.004     14.0   1.2--163   0.035
   More than one doctors visit due to illness in the previous 12 months                                                                                                 47                                    255   2.6    1.2--5.7      0.013                       
  Mental health                                                                                                                                                                                                                                                      
   Major depressive disorder                                                                                                                                            26                                    54    4.5    2.5--8.0      \<0.001                     
  Life stressors                                                                                                                                                                                                                                                     
   Two or more major stressful events in previous 12 months                                                                                                             36                                    83    5.2    3.0--9.2      \<0.001                     
  Drug use (at least monthly)                                                                                                                                                                                                                                        
   Cigarettes                                                                                                                                                           32                                    88    3.6    2.1--6.4      \<0.001                     
   Marijuana                                                                                                                                                            20                                    59    2.6    1.4--4.8      0.001                       
   Benzodiazepines ('benzos')                                                                                                                                           11                                    25    3.1    1.4--6.7      0.003                       
   Opiates                                                                                                                                                              4                                     6     4.3    1.2--15.8     0.016                       
  HIV disclosure and stigma since HIV diagnosis                                                                                                                                                                                                                      
   Been made to feel ashamed for having HIV                                                                                                                             39                                    157   2.5    1.4--4.4      0.001                       
   Been made to feel blamed for having HIV                                                                                                                              29                                    120   1.9    1.1--3.4      0.017                       
   Been made to feel avoided for having HIV                                                                                                                             38                                    145   2.7    1.5--4.7      \<0.001                     
   Been made to feel awkward for having HIV                                                                                                                             41                                    175   2.4    1.3--4.3      0.003                       
  HIV healthcare and treatment access                                                                                                                                                                                                                                
   HIV managed by a health centre specialized in HIV care                                                                                                               24                                    91    2.0    1.2--3.6      0.013                       
   HIV managed by a community based general practitioner                                                                                                                33                                    125   2.4    1.4--4.1      0.002                       
   Accessed hospital-based pharmacy                                                                                                                                     39                                    183   1.9    1.1--3.3      0.027                       
   Requires home or community care services                                                                                                                             7                                     6     8.0    2.6--24.7     \<0.001                     
   Accessed HIV-related community organization or peer support groups in management of HIV                                                                              18                                    49    2.8    1.5--5.2      0.001                       
   Receiving care from primary HIV physician for \<10 years                                                                                                             35                                    152   1.9    1.1--3.4      0.019                       
   Other specialist(s) involved in care                                                                                                                                 47                                    231   2.2    1.1--4.1      0.018                       
   No other healthcare specialists/workers involved in HIV care/treatment                                                                                               48                                    232   2.4    1.2--4.6      0.010                       
   Sees a physiotherapist and does not pay                                                                                                                              7                                     8     10.5   1.1--102.5    0.023                       
   Greater than one missed appointment in the previous 12 months                                                                                                        15                                    39    2.8    1.4--5.5      0.002                       
   Felt not at all informed about ART\'s impact on lifestyle when first started ART                                                                                     26                                    107   1.8    1.1--3.2      0.030                       
   When first started ART felt not at all informed or only somewhat informed on all of: side effects, benefits, dosage requirements, impact on lifestyle, own regimen   10                                    29    2.3    1.1--5.0      0.032                       
   When starting ART, main reason was to prevent transmission to partners uninfected with HIV                                                                           17                                    58    2.2    1.1--4.0      0.015                       
   When starting ART, main reason was to prevent transmission to others uninfected with HIV in the community                                                            17                                    51    2.5    1.3--4.7      0.004                       
   When starting ART, main reason was due to high viral load                                                                                                            39                                    154   2.7    1.5--4.8      0.001                       
   When starting ART, main reason was due to low CD4^+^ cell count                                                                                                      39                                    186   1.9    1.0--3.4      0.020                       
   When starting ART, main reason was following own request                                                                                                             13                                    41    2.2    1.1--4.5      0.020                       
  ART regimen, side effects, consistent use, adherence                                                                                                                                                                                                               
   Sometimes forgets to take ART                                                                                                                                        41                                    157   2.9    1.6--5.2      \<0.001                     
   Careless at times about taking ART                                                                                                                                   18                                    59    2.3    1.2--4.2      0.009                       
   Stops taking ART when feeling worse                                                                                                                                  15                                    29    3.9    1.9--7.8      \<0.001                     
   In the last week, has not taken ART (at least once)                                                                                                                  21                                    50    3.4    1.9--6.3      \<0.001                     
   In the past weekend, has missed ≥3 ART doses                                                                                                                         20                                    50    3.2    1.7--5.9      \<0.001                     
   In the past 12 months, delayed or interrupted ART                                                                                                                    16                                    12    10.8   4.8--24.4     \<0.001                     
   Prior to 12 months ago, delayed or interrupted ART                                                                                                                   23                                    49    4.4    2.4--8.0      \<0.001                     
   Has had ART side effects in previous 12 months                                                                                                                       47                                    205   2.9    1.5--5.5      0.001                       
   Delayed or interrupted concomitant medications prior to 12 months ago                                                                                                38                                    11    66.0   28.8--151.4   \<0.001                     
  ART-related necessity concerns                                                                                                                                                                                                                                     
   Necessity concerns score, lower necessity beliefs than sample                                                                                                        39                                    164   2.3    1.3--4.1      0.003                       
  Quality of life                                                                                                                                                                                                                                                    
   PROQOL-HIV, lower quality of life than sample                                                                                                                        45                                    150   4.4    2.4--8.1      \<0.001                     

AOR, adjusted odds ratio; ART, antiretroviral therapy; CI, confidence interval; OR, odds ratio; NGO, non-governmental organisation; PROQOL-HIV, patient reported outcomes quality of life - HIV; SNAE, serious non-AIDS event.
